Low-molecular weight heparins in coronary artery disease.
Recently published trials strongly support the use of low-molecular weight heparins in the treatment of unstable coronary syndromes. These agents provide an alternative to heparin that is at least as effective and safe, and does not require intravenous infusions or meticulous monitoring. Although comparative trials are not yet available, the available evidence allows for selection of specific agents in acute management of unstable angina. This review summarizes the current clinical data supporting the use of these agents.
Hunt
D
D
Section of General Internal Medicine, Ben Taub General Hospital, Baylor College of Medicine, 1504 Taub Loop, 2RM81-001, Houston, TX 77030, USA. danielh@bcm.tmc.edu
D000789:Angina, Unstable / Q000175:diagnosis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis; D016896:Treatment Outcome
D006495:Heparin, Low-Molecular-Weight